Nalagarh, Himachal Pradesh, India: Theon Pharma today announced the launch of India’s first Vonoprazan–Amoxicillin–Clarithromycin Triple Therapy Kit, following approval from the Central Drugs Standard Control Organisation (CDSCO). With this milestone, Theon becomes the first pharmaceutical company in India to introduce a ready-to-use, co-packaged Potassium-Competitive Acid Blocker (PCAB)-based triple therapy kit for the eradication of Helicobacter pylori (H. pylori) infection and the treatment of associated peptic ulcer disease in adult patients.
The launch represents a significant advancement in India’s gastroenterology segment by bringing an internationally accepted treatment approach to Indian healthcare professionals and patients. Designed to provide a complete 14-day treatment regimen in a convenient co-packaged format, the kit combines Vonoprazan, Amoxicillin, and Clarithromycin, enabling simplified prescribing, improved patient compliance, and better clinical outcomes.
Globally, Vonoprazan-based triple therapy has emerged as an important advancement in H. pylori eradication due to its rapid, potent, and sustained acid suppression, which enhances antibiotic effectiveness and contributes to higher eradication rates compared with conventional proton pump inhibitor (PPI)-based regimens.
Addressing a Major Gastrointestinal Health Burden
H. pylori remains one of the most prevalent chronic bacterial infections in India, directly linked to chronic gastritis, gastric/duodenal ulcers, dyspepsia, MALT lymphoma, and an elevated long-term risk of gastric adenocarcinoma.
- High Disease Prevalence: A comprehensive 2025 meta-analysis spanning 52 studies across 15 Indian states demonstrated a pooled H. pylori prevalence of 54% among symptomatic GI patients and 61% in asymptomatic individuals.
- Declining PPI Efficacy: Over the past decade, standard Proton Pump Inhibitor (PPI)-based triple therapies have suffered declining eradication success due to CYP2C19 genetic polymorphism-driven drug metabolism, delayed acid suppression, and mounting antimicrobial resistance.
By introducing India’s first PCAB-based triple therapy kit, Theon Pharma aims to resolve 2 major hurdles in current gastrointestinal disease management -Tackling rising antibiotic resistance and poor patient complianceA New Standard in H. pylori Therapy
The Vonoprazan–Amoxicillin–Clarithromycin Kit brings together three established therapeutic agents in a single co-packaged regimen for twice-daily administration over 14 days.
- Rapid & Sustained Gastric pH Control: Unlike conventional proton pump inhibitors, Vonoprazan is a next-generation Potassium-Competitive Acid Blocker that provides rapid, potent and sustained acid suppression.
- Enhanced Antibiotic Stability: Maintaining a consistently higher gastric pH can create a favourable environment for antibiotics Amoxicillin and Clarithromycin to act against H. pylori.
- Regulatory approval: Alignment with USFDA Approval, The CDSCO has approved Vonoprazan tablets in India for multiple acid-related disorders, including reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of combination therapy for H. pylori eradication. It’s an established treatment option and is increasingly incorporated into clinical practice because of its favorable eradication outcomes and patient-friendly dosing schedule.
The co-packaged presentation also minimizes dispensing errors, simplifies treatment initiation, and encourages better adherence by providing patients with the complete therapy in a single, easy-to-use pack.Strengthening India’s Access to Advanced Therapies
For healthcare providers, pharmaceutical marketers, and patients, the co-packaged Combikit resolves traditional compliance bottlenecks:
- Clear AM/PM Dose Coding: The innovator-equivalent Alu PVC blister design features distinct color-coded day and night dosing, minimizing pill confusion and treatment discontinuation.
- Complete 14-Day Solution: Packaging all three active ingredients into a single, unified kit eliminates multi-prescription complexity and dispensing errors.
- Value Addition for Pharma Partners: Designed with premium packaging aesthetics and flexible branding spaces, the kit provides pharmaceutical marketing partners a turnkey, highly differentiated portfolio asset in the high-growth gastroenterology segment.
Leadership Perspective:Commenting on the launch, Mr. Amit Bansal, Managing Director, Theon Pharma, said, “At Theon Pharma, our vision is to bring globally relevant pharmaceutical innovations to Indian patients through quality, science and accessibility. The launch of India’s first Vonoprazan–Amoxicillin–Clarithromycin Triple Therapy Kit reflects our commitment to addressing unmet medical needs with differentiated, evidence-based solutions. By combining advanced pharmaceutical engineering with world-class CDMO capability, we are empowering our brand partners and physicians with a modern tool to strengthen India’s healthcare ecosystem through innovation, world-class manufacturing, and a patient-centric approach.”
Mr. Punit Bansal, Director, Theon Pharma, said, “Helicobacter pylori management in India has reached a critical juncture where standard PPI regimens are no longer yielding optimal eradication rates. Introducing a co-packaged Vonoprazan-based regimen bridges this gap, bringing international guideline-recommended care to local clinical practice. This 14-day kit simplifies the therapeutic burden for patients while giving gastroenterologists and physicians a dependable, first-line weapon to prevent chronic GI complications.”
About Theon Pharmaceuticals Ltd.
Theon Pharmaceuticals Ltd. is an innovation-driven pharmaceutical manufacturer and CDMO headquartered in Chandigarh, with state-of-the-art, PICS-certified manufacturing facilities in Himachal Pradesh & Punjab. Specializing in advanced oral solid dosage forms, multi-layer tablets, and specialized combikits, DPI & liquid Injectibles. Theon serves top-tier domestic pharma companies as well as international markets across Asia, Africa, and Latin America and expanding to European Territory in years to come.
Disclaimer: The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
